0001209191-23-041617.txt : 20230706 0001209191-23-041617.hdr.sgml : 20230706 20230706172059 ACCESSION NUMBER: 0001209191-23-041617 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230703 FILED AS OF DATE: 20230706 DATE AS OF CHANGE: 20230706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fenton Mary Kay CENTRAL INDEX KEY: 0001378589 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 231074488 MAIL ADDRESS: STREET 1: ACHILLION PHARMACEUTICALS STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Talaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 570 PRESTON ST. STREET 2: SUITE 400 CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 502-398-9250 MAIL ADDRESS: STREET 1: 93 WORCESTER STREET CITY: WELLESLEY STATE: MA ZIP: 02481 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-07-03 0 0001827506 Talaris Therapeutics, Inc. TALS 0001378589 Fenton Mary Kay C/O TALARIS THERAPEUTICS, INC. 93 WORCESTER ST. WELLESLEY MA 02481 0 1 0 0 Chief Financial Officer 0 Common Stock 2023-07-03 4 F 0 12946 3.08 D 68054 D The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023. /s/ Mary Kay Fenton 2023-07-06